ClinicalTrials.gg
RecruitingNCT05565573Updated Oct 4, 2022

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

A Phase 2/3 interventional study of Medroxyprogesterone Acetate 500 MG Oral Tablet and Levonorgestrel-Releasing Intrauterine System in Fertility Sparing, sponsored by Hua Li. Recruiting at 1 site in China. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Hua Li · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
Female
01

Study summary

In modern society, endometrial cancer (EC) and atypical hyperplasia is the most frequent desease which can affect the fertility of young patients. For young patients, there is a growing need to treat tumors and fertility sparing. Advaced studies have confirmed thatfertility preservation therapy has better tumor and pregnancy outcomes in specific patients with early gynecological tumors. Clinically, evidence-based guidelines are urgently needed to guide the screening and treatment of women who are suitable for fertility preservation. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies.The present study aims to compared the therapeutic effect of Medroxyprogesterone acetate (MPA) and Levonorgestrel-releasing intrauterine system (LNG-IUS) in early-stage endometrioid carcinoma and atypical hyperplasia patients

02

Conditions studied

  • Fertility Sparing
03

In context

Lead sponsor

Hua Li is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≤ 45 years old;
  2. Diagnostic curettage pathology is highly differentiated endometrioid adenocarcinoma;
  3. pelvic augmentation MRI or / and vaginal color ultrasound Doppler examination, tumor confined endometrium;
  4. No suspicious lesions;
  5. Endometrial pathological tissue specimens with strong positive expression of estrogen and progesterone receptors;
  6. Blood CA125 is normal;
  7. no progesterone therapy and to pregnancy;
  8. The patient himself has a strong desire to preserve fertility, and the patient should fully understand that fertility preservation treatment is not the standard treatment method;
  9. Conditional acceptance of close follow-up.

Exclusion criteria

Exclusion Criteria:

  1. type II endometrial cancer;
  2. Patients with abnormal liver and kidney function and other to progesterone therapy;
  3. Other parts of the body are concurrent or successively complicated by other malignant tumors;
  4. The patient and his/her family are unable to sign the form for any reason;
  5. Unconditional follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Medroxyprogesterone acetate

    Administered MPA at a dosage of 500 mg/d concurrently

    Drug: Medroxyprogesterone Acetate 500 MG Oral Tablet

  • Experimental
    LNG-IUS

    Go through LNG-IUS insertion

    Device: Levonorgestrel-Releasing Intrauterine System

Interventions

  • DrugMedroxyprogesterone AcetateStudies of Medroxyprogesterone AcetateMedroxyprogesterone Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day

    Also known as: MPA

  • DeviceLevonorgestrel-Releasing Intrauterine System

    Uterine cavity insertion

    Also known as: LNG-IUS, 52-mg LNG-IUS,Mirena

06

What researchers measure

Primary outcomes

  1. Complete response rate

    The 24-week CR rate will be calculated in two groups.

    Time frame: 24-week

Secondary outcomes

  1. Time to achieve complete response

    The median CR time will be calculated in two groups

    Time frame: From date of randomization until the date of CR, assessed up to 24 weeks

  2. The pregnancy rate

    Rate of fertility outcomes

    Time frame: Up to 2 years after the treatment

  3. The live-birth rate

    Rate of fertility outcomes

    Time frame: Up to 2 years after the treatment

07

Study locations

1 of 1 sites recruiting
  • Bei Jing Chao-Yang Hospital
    Beijing, Beijing 100025, China
    Recruiting
    • Hua Li, Ph.D · Contact+86 010 85231831
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Jul 2024, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 4, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
Jul 1, 2024
CompletionEst.
Nov 1, 2025
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05565573
Lead sponsor
Hua Li
Responsible party
Hua Li (Department of Obstetrics and Gynecology, Beijing Chao Yang Hospital) — Sponsor-investigator
First posted
Oct 4, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Jul 1, 2024 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Oct 4, 2022

Study contacts

Hengzi Sun, Ph.D
Contact
summerel1990@163.com
+86 18811151901
Hua Li, Ph.D
study chair · Beijing Chao Yang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Medroxyprogesterone Acetate

Start the discussion